Management of Glaucoma in Pregnancy

Short Title: Glaucoma in pregnancy reviewed

Sunu Mathew, MBBS, DNB¹, Alon Harris, MS, PhD, FARVO¹, Colin M Ridenour, MD¹, Barbara M Wirostko, MD, PhD², Kendall M Burgett, BS¹, Molly D Scripture BS¹, Brent Siesky, MS, PhD¹

¹Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, USA
²Moran Eye Center, Salt Lake City, UT, USA

Corresponding author:
Alon Harris, MS, PhD, FARVO
Lois Letzter Professor of Ophthalmology
Professor of Cellular and Integrative Physiology, Department of Ophthalmology
Eugene and Marilyn Glick Eye Institute Indiana University School of Medicine
1160 West Michigan Street
Indianapolis, IN 46202
Phone: (317) 278-0177, Fax: (317) 278-1007
Email: alharris@indiana.edu

Pre’cis
Management of glaucoma in pregnancy is challenging. The optimal treatment option needs to provide adequate control of IOP for the mother while maintaining minimal risk for the fetus.

This is the author's manuscript of the article published in final edited form as:
Abstract
Management of glaucoma during pregnancy represents a challenge for the physician. Important disease and patient health decisions begin even prior to conception and continue throughout pregnancy and breastfeeding. Data on this topic is limited due to ethical and legal constraints and challenges of conducting large, prospective, and randomized clinical trials on this patient population. Our review suggests that individually, intraocular pressure is lower in a pregnant woman when compared to a non-pregnant woman. Importantly, the medical management of glaucoma during pregnancy poses special challenges due to the possibility of adverse effects of medications on the fetus and newborn. Laser trabeculoplasty and traditional filtration surgery, as well as minimally invasive glaucoma surgery, represent non-drug management options. Thus, managing glaucoma in pregnancy is a delicate balance between treatment to prevent damage to the optic nerve in the mother and avoidance of interventions potentially harmful to the fetus. This literature review of published individual and population-based studies was performed in order to explore current knowledge and guidelines in the management of glaucoma in pregnancy.

Keywords: glaucoma, pregnancy, lactation, intraocular pressure, anti-glaucoma medications
Epidemiology
Managing chronic diseases in pregnant women poses a unique challenge for physicians; the risks of limiting treatment options for the mother and the risk of exposing the fetus to disease management interventions. In addition, there is the added risk due to alterations in the physiology and hemodynamic state of the pregnant woman. Dueling paradigms of treatment and safety need to be carefully evaluated and glaucoma is no exception to this challenge. Importantly ophthalmologists often have limited confidence in addressing this subject. Vaideanu et al. conducted a survey of all consultant ophthalmologists in the United Kingdom, and their results indicated that many ophthalmologists are uncertain about the optimal strategy in the management of glaucoma in pregnancy. Due to the ethical and legal constraints of conducting large, prospective, and randomized clinical trials on this patient population, the data on this subject is limited. Without rigorous clinical research, physicians must rely on alternative forms of research and scientific literature to guide them in their decision making processes. There are case reports which describe women with glaucoma whose intraocular pressure (IOP) was difficult to control during pregnancy, despite medical and surgical intervention. Therefore it is important for physicians to be careful and knowledgeable while treating this patient population. Glaucoma has traditionally been considered a disease of old age, a survey of 3,494 patients under 40 who were examined in an urban optometric center showed that 0.4% of the sample had glaucoma and an additional 0.2% had suspected glaucoma. Thus although the prevalence is not very high in women of childbearing age, the decision to have children can significantly impact glaucoma management strategies.

This review explores the medical management of glaucoma in pregnancy and examines the various antiglaucoma drugs and their safety and efficacy during pregnancy and lactation. Articles from Pubmed published from 1952-2017 were identified by using the keywords, glaucoma, pregnancy, lactation, intraocular pressure, and antiglaucoma medications.

Preconception planning
Women of childbearing age may have a history of glaucoma and already be on a treatment regimen. The situation is more complicated if pregnancy is unplanned since the greatest risk of treatment induced adverse effects to the fetus is in the first trimester of pregnancy: during organogenesis. Preconception counseling is the best recommended strategy in women of childbearing age with glaucoma. This helps women to understand potential benefits and risks of various treatment modalities, promotes better cooperation in evaluating IOP levels and fluctuations at more frequent intervals, as well as evaluating optic nerve and visual field function in order to assess the baseline status. It also helps to determine the risk of observation when treatment is discontinued, or fewer medications are entertained during pregnancy. If the glaucoma is uncontrolled, laser treatment or surgical intervention may be undertaken prior to conception to avoid side-effects of glaucoma medications during pregnancy.

The eye in pregnancy
Multiple studies have demonstrated that IOP in pregnant females is on average lower than non-pregnant females. Initial theories focused on the hormonal levels that fluctuate during pregnancy, such as estrogen, relaxin, progesterone, and β-human chorionic gonadotrophin. Later it was shown that the aqueous humor formation rate does not change during pregnancy, but that outflow facility increases during pregnancy, causing a
decrease in IOP. Ebeigbe et al. have shown that with advancing pregnancy, IOP decreases from 14.7mmHg in the first trimester to 11.0mmHg in the third trimester. In addition, lower IOP has been associated with less severe fluctuations in IOP over the course of the day during the third trimester. The ocular hypotensive effects of pregnancy also extend to patients with preexisting ocular hypertension, although the time course differed between patient groups. Qureshi et al. found that, in normotensives, the significant decrease in IOP occurred in the 18th week, while the decrease occurred later in the course of pregnancy in ocular hypertensive patients. In ocular hypertensive subjects, pregnancy may even bring the IOP down to within normal limits. Systemic hypertension has been shown to influence IOP in non-pregnant patients; however, the evidence in the pregnant population is mixed. Some studies found no significant difference in IOP in the third trimester between hypertensive and normotensive pregnant women, while others found that the IOP in pregnant hypertensives was higher than the non-hypertensive pregnant women in the third trimester. It was also found that the decrease in IOP was independent of systemic BP, body weight and height. Evidence has also shown that multigravida have lower IOP than primigravidae, who in turn have lower IOP than non-pregnant women, although the exact mechanism of this difference is largely unknown. Despite our understanding of IOP changes that occur in non-glaucomatous pregnant females, we have limited data in pregnant patients with glaucoma. Brauner et al. followed 15 pregnant women with glaucoma throughout pregnancy and their individual disease course was mixed. In over half (57.1%) of the eyes, IOP remained stable and there was no progression in the visual field. In 17.9% of eyes, there was visual field progression with stable or increased IOP. In 17.9% of eyes remained stable despite increasing IOP and the remaining eyes (7.1%) were non-compliant to medications. While the natural course of IOP in healthy people decreases throughout pregnancy, the course of glaucoma during pregnancy is variable, and women must be monitored closely during pregnancy. Thus, managing IOP in pregnant women remains a challenge which is necessary to prevent pregnancy related vision loss.

Some studies claimed that hormonal changes during pregnancy do not affect corneal biomechanics, while several other studies found that pregnancy was associated with increase corneal curvature, corneal volume, corneal innervation, and corneal thickness. This may be because of the various hormones on the cornea during pregnancy. Pregnancy is known to worsen diabetic retinopathy, as well as retinal detachments, central serous chorioretinopathy, and retinal vascular occlusive diseases. Retinal blood vessels have classically been examined as a way to monitor pre-eclampsia and eclampsia. The choroid is a highly vascularized tissue characterized by the highest blood flow to tissue volume ratio in the whole body. This makes it especially susceptible to hemodynamic and hormonal changes taking place in pregnancy, which may affect its thickness. Choroidal thickness has been found to be increased in pregnant versus non-pregnant women, and this thickening was maximum in the second trimester of pregnancy. The circulating blood volume increases from week 5-6 of pregnancy, and most rapidly from weeks 20 to 24. As a result of the effect on the hemodynamics of the cardiovascular system in pregnancy, a decrease in vascular resistance prevails over the effect of an increase in blood volume; and thus results in a decrease in systolic and diastolic pressure. Laser Speckle Flowgraphy (LSFG) parameters have shown a
decrease in resistance in the retinal blood vessels in normal pregnancy. Flow acceleration index (FAI) and resistive index (RI) values showed a significant decrease in the 3rd trimester, while blowout score (BOS) increased in the 3rd trimester and mean blur rate (MBR) showed no significant changes throughout pregnancy. In addition, mean arterial pressure (MAP) was negatively correlated with FAI and RI while positively correlated with BOS. Thus, retinal vasculature provides a highly sensitive reflection of physiological changes in vascular resistance due to pregnancy.34, 35

**Labor in Glaucomatous Patients**

Some studies have postulated that IOP during labor can vary depending on the stage of labor.36 Sixty-four (64) non-glaucomatous patients were evaluated during each stage of labor. This study found that mean IOP increased by 1.4 mm Hg during the course of labor which was found to be statistically significant, and then decreased by 3.0 mm Hg immediately after delivery. The IOP returned to pre-labor levels in all patients by 72 hours after delivery. It was postulated that an increase in oxytocin levels during labor leads to capillary constriction and a decrease in aqueous outflow.36 More recent studies performed on patients who received epidural anesthesia showed a mild increase in IOP and mean ocular perfusion pressure during the second stage, but this was not statistically significant.37 There is no evidence in the literature linking oxytocin with a rise in IOP.37 Whether this has any effect on the progression of glaucoma has not been studied, as the effects of a small change in IOP for a short period of time, on glaucomatous progression is unknown.38 While not a part of the natural disease process, loss of large amounts of blood during labor may potentially lead to transient hypotension and ischemia, with an increased risk for optic nerve damage.39

**Medical Management of Glaucoma**

The pregnant (or planning to be pregnant) glaucoma patient presents a unique clinical challenge for ophthalmologists. The clinician is faced with balancing the risk of glaucomatous disease progression in the mother against the potential risks of interventions to the fetus or newborn child. The course of glaucoma in pregnancy may be complex. While numerous studies have supported the ocular hypotensive effects of pregnancy, including Qureshi et al. who found that patients with ocular hypertension also have reduced IOP in pregnancy,15 the IOP data in pregnant glaucoma patients remains undefined. In light of the limited and mixed results, it is important to evaluate each patient based on their individual glaucoma risk, need for treatment, and regular monitoring throughout pregnancy. Medical treatment of glaucoma carries a potential health risk to the developing fetus. Because of this potential risk, it is important to reduce the systemic absorption of topical glaucoma medications. Systemic absorption may be reduced by nasolacrimal occlusion (NLO), punctual plugging, or eyelid closure. Zimmerman et al. found that NLO or eyelid closure for 5 minutes reduced systemic absorption over 60%. Both NLO and eyelid closure are safe, simple and effective ways to minimize dosage as well as side effects.40

When evaluating the individual risk of medications, it is useful to review the FDA Pregnancy Categories of various glaucoma medications (Table 1). While we do not have randomized clinical trials in pregnant glaucoma patients, animal studies and case reports can aid ophthalmologists when making treatment decisions and choosing pharmacologic therapies. The FDA Pregnancy Categories for medications include classes A, B, C, D and X,41 with glaucoma medications occupying classes B and C.3 To qualify as a Category A
There must be human studies that have failed to demonstrate risk to the fetus. There are currently no randomized prospective human studies for glaucoma medications in pregnancy. Furthermore, they are unlikely to be performed in the future due to ethical conflicts. Category B medicines include those where animal studies fail to demonstrate a risk to the fetus, but there are not adequate studies in pregnant women to elevate to Category A. The Category C medications demonstrate adverse effects in animal fetuses, but again no adequate studies have been performed in humans. Category C medications may still benefit pregnant women despite the negative effects seen in animal models. Category D medications carry known human risk based on a history of adverse reactions, although their use may be warranted in some cases. Finally, Category X medications have shown fetal abnormalities in either humans or animals. The risks clearly outweigh the potential benefits from use of category X medications.

The most common preservative in anti-glaucoma drugs is benzalkonium chloride (BAK). Animal studies on rats have shown a dose-related increase in fetal resorption and death, as well as a reduction in litter size and weight. Minor defects in the sternum were seen in fetuses exposed to a single dose of 100 and 200 mg/kg. The concentration of BAK in anti-glaucoma eye drops varies from 0.005% to 0.2%. In this dose, it can disrupt the lipid layer of the tear film and also cause evaporation of tears. It has also been shown to have cellular toxicity on caliciform cells. Systemically it may even cause a delayed type of hypersensitivity reaction (Type-IV).

Beta-blockers: Beta-blockers are one of the first line treatment options for glaucoma patients and are FDA pregnancy category C. This class of medication is typically prescribed as a topical preparation, but the IOP lowering effects occur with the systemic preparations as well. The topical beta blockers that are commonly used include timolol maleate, timolol hemihydrate, betaxolol, carteolol, levobunolol, and metipranolol. All of these medications, except for betaxolol, are non-selective beta antagonists. The non-selective agents have both beta-1 and beta-2 antagonistic activity. Beta-1 receptors are primarily located in cardiac tissue, and the effect of beta-1 selective antagonists is a decrease in heart rate. Beta-2 receptors are primarily located on the arteries of skeletal muscle and bronchioles of the lungs, and beta-2 selective antagonists activation lead to bronchoconstriction. Betaxolol is a beta-1 selective antagonist; therefore, it avoids some of the systemic effects of the non-selective agents, although for IOP reduction it is less efficacious than non-selective medications. Additionally, carteolol, a non-selective beta antagonist, has intrinsic sympathetic activity and therefore some of the antagonistic actions are reduced.

The beta blockers decrease IOP by decreasing aqueous humor production via inhibition of cAMP in the ciliary epithelium. The IOP lowering effects have been found with both systemic and topical beta-blocker use. While some ophthalmologists may be hesitant to use this medication in pregnant women, obstetricians frequently use systemic beta blockers in pregnancy to control hypertension. Some of the hesitation stems from both theoretical and reported concerns for neurological, cardiopulmonary, and growth restriction complications in the newborn. The neurological concerns stem from the side effects of lethargy, confusion, and depression seen from beta-blocker use. Studies support that by switching from timolol to betaxolol, which is a selective antagonist, the CNS effects are reduced.

Data on the use of antiglaucoma medications, in particular beta-blockers, has yielded
conflicting conclusions. Ho et al. conducted a population-based study (n=244) in order to examine the relationship between the incidence of having a low-birth-weight (LBW) infant and the use of antiglaucoma medications during pregnancy. They concluded that while there was no significant difference in the risk of having LBW infants between mothers prescribed beta-blockers and mothers in the comparison cohort, there was a significantly higher risk of having a LBW infant for mothers prescribed other topical antiglaucoma medications compared to the control group.\textsuperscript{53} Similarly, Brauner et al found no significant complications including LBW.\textsuperscript{17} Of particular note is that they instructed all pregnant women to use punctual occlusion after installation of eyedrops to decrease systemic absorption. On the other hand, Razeghinejad et al in a small study found a statistically significant reduction in birth weight in infants born to mothers on topical beta-blockers.\textsuperscript{54} However, it should be noted that their patients were on topical combination therapy. Beta-blockers are known to affect cardiac physiology with side effects of bradycardia and possible arrhythmia. A published case report by Wagenvoort et al described a fetus with bradycardia and arrhythmia when the mother was on topical timolol. These side effects improved following a reduction in the medication concentration\textsuperscript{55} and other studies have shown no evidence of changes in heart rate.\textsuperscript{56} Furthermore, beta-blockers can be actively secreted into breast milk and cause potential adverse effects in breastfed infants. In one case study, the concentration of timolol in breast milk was determined to be six times that of the plasma following topical ophthalmic use\textsuperscript{57} and another study found betaxolol to be three times more concentrated in breast milk than in the plasma.\textsuperscript{58}

Sympathomimetics: These are the only topical antiglaucoma medications classified as category B\textsuperscript{3}. Non-selective agonists and selective alpha agonists like clonidine and apraclonidine are not used frequently in the treatment of chronic glaucoma due to the side effects such as nausea, vomiting, palpitations, and difficulty in micturition which are associated with chronic use.\textsuperscript{59-61} Brimonidine is the only drug in this category which is used on a long-term basis. Animal studies on pregnant rats and rabbits have revealed no damage to the fetus at doses much higher than the dose used at therapeutic levels in humans.\textsuperscript{62} Although considered safe to use in pregnancy, brimonidine is thought to be secreted in breast milk and should be discontinued in the third trimester as it causes central nervous system depression, hypotension, and apnea in infants.\textsuperscript{63,64} Carbonic anhydrase inhibitors: Acetazolamide and methazolamide are oral carbonic anhydrase inhibitors (CAI) used for glaucoma management. These agents are category C for use during pregnancy.\textsuperscript{3} Acetazolamide at high doses has been shown to produce birth defects in animals.\textsuperscript{65,66} However clinical or experimental studies looking at the adverse effects of acetazolamide on pregnancy outcomes in humans have shown mixed results.\textsuperscript{52,67-69} One isolated incidence of limb anomalies has been found in literature, but other studies\textsuperscript{70,71} have not shown any limb anomalies following systemic use of Carbonic anhydrase inhibitors in pregnancy. So if the clinical situation warrants the use of systemic acetazolamide, then the drug could be administered with appropriate informed consent. Animal studies have shown decreased weight gain in the offspring of lactating rats who have been exposed to very high doses of topical CAI.\textsuperscript{72,73} However, recent reports have shown mixed results in humans. It was earlier thought to be safe to use in humans but recently, there are a few reports of low birth weight\textsuperscript{53} and defects in renal tubular function in the newborn following maternal use of topical CAI.\textsuperscript{74} Although low plasma levels of
acetazolamide have been reported in infants exposed to the medication through breast milk, the American Academy of Pediatricians has approved the use of CAIs during lactation, provided there is close monitoring of oral formulations. Prostaglandin analogs: Bimatoprost, latanoprost, travoprost, and tafluprost are prostaglandin-F2 analogs used as topical eye drops in patients with glaucoma. They belong to category C for use during pregnancy. Prostaglandins are also used systemically to induce labor by stimulating smooth muscle contraction. The contractile function has been demonstrated specifically of latanoprost, travoprost, and bimatoprost in non-pregnant uterus which had been isolated in rat models. Fortunately, there are no reports of premature labor in humans associated with the use of these drugs topically for glaucoma. There is no data available on the effect of tafluprost eye drops on the uterus. It has been shown that prostaglandin analogs are excreted in the breast milk of animals, although it is not known if they are excreted in the breast milk of humans. Whether or not topically administered medications reach plasma concentrations that could induce adverse effect on the pregnancy or on the fetus remains controversial. Although birth defects have been reported following the prenatal use of systemic prostaglandins, a small study by De Santis et al on 11 pregnant women showed that topical latanoprost exposure caused no adverse effects on either the pregnancy or the newborn. The difference in adverse events in this study compared to animal studies may be due to dosage levels. While De Santis's study found no evidence for adverse outcomes, the study was small and involved a 46-year-old female with miscarriage; however, this may be due to her advanced age. Being prodrugs, latanoprost and travoprost have the advantage of being converted into the active form once they pass the cornea with increased intraocular penetration and decreased local and systemic side effects, however, use in the case of severe glaucoma uncontrolled with other topical medication has not been prospectively studied. Latanoprostene is another prostaglandin-F2 analog which has entered the market.

A new class of drug which has entered the market is Netarsudil which is an inhibitor of Rho kinase and norepinephrine transporter. It increases outflow of aqueous humor and decreases episcleral venous pressure. However, there are no studies which have looked into its safety during pregnancy and lactation.

Parasympathomimetics, or cholinergic agents, are classified as category C drugs. Although pilocarpine and carbachol injected into the yolk sac have demonstrated teratogenic and adverse fetal effects in animals Kooner et al. found no association between congenital abnormalities and the use of topical cholinergic agents during the first 4 months of gestation. Cholinergic receptors are found on the placenta, and it is thought that they are linked to myometrial and placental prostaglandin release and regulation of placental perfusion. There are reports of hyperthermia, seizures, or restlessness in neonates and therefore these medications are generally avoided in the postpartum period. Due to the availability of safer and more effective drugs with other classes of antiglaucoma medications, parasympathomimetics are not used in management of glaucoma in pregnancy. (Table 2)

**Laser filtration procedure in Glaucoma**

When medical treatment fails or is not an option to control IOP or there is progression of visual field damage in a pregnant female with glaucoma, laser filtration options need to be considered. Laser procedures are useful to reduce or eliminate the use of medications...
which may be potentially harmful to the fetus. When considering laser procedures, special consideration must be given to the angle of the anterior chamber. Glaucoma in this age group could be secondary to congenital conditions like Axenfeld-Reiger’s syndrome, Sturge Weber syndrome, Peter’s anomaly or aniridia. It may also be secondary to inflammatory conditions like uveitis or trauma. These may prove to be challenging in terms of management.

Laser procedures offer the least risk to the unborn fetus. Advantages over incisional surgery are that it requires only topical anesthesia, can be performed in an upright position, is an outpatient procedure with very little pre- and post-operative medication requirement, and patients demonstrate faster rehabilitation, all of which are of advantage both in early and advanced stages of pregnancy. The most frequently done procedure is neodymium: yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy for narrow-angle glaucoma. Another procedure performed on the iris is the laser peripheral iridoplasty in which laser burns are applied to the peripheral iris to facilitate widening of the anterior chamber angle or to lyse peripheral anterior synechiae. Argon laser trabeculoplasty in which evenly spaced burns are placed on the anterior trabecular meshwork for 180 or even 360 degrees of the angle. It causes both structural and coagulative damage to the tissues of the trabecular meshwork. Selective laser trabeculoplasty, on the other hand, is less disruptive to the tissues. The laser-induced thermal damage is confined to pigmented areas within an irradiated tissue. Using micropulse diode laser, the thermal spread of laser energy and consequent coagulative damage can be avoided. However, laser filtration procedures are not very effective in controlling IOP in patients younger than 50 years of age.

**Surgery in Glaucoma**

Surgical options include traditional filtration surgery and minimally invasive glaucoma surgery (MIGS). It should be noted that drugs used during surgical interventions and for postoperative care should be reviewed and considered as sources of risk. There are several risks to be considered when planning invasive filtration surgery in a pregnant glaucomatous patient. These include the risks of local and systemic anesthetic medications and pre- and post-operative medications. Inhaled anesthetic agents and central nervous system depressants used to anesthetize the patient can be harmful to the fetus. This is particularly true of general anesthetic agents, which have been shown to cause an increased incidence of low birth weight and neural tube defects when administered to the mother in her first trimester. Most local anesthetics have not been shown to be teratogenic in humans and are considered relatively safe for use during pregnancy. Lidocaine and etidocaine are classified as group B and bupivacaine and mepivacaine are in group C because they have a tendency to induce fetal bradycardia. Retrobulbar anesthesia may produce more systemic absorption than subconjunctival and anterior sub-Tenon’s anesthesia combined with topical anesthesia for glaucoma surgery. Position of the patient during surgery is important especially in second and third trimester of pregnancy. The gravid uterus may compress the aorta or inferior vena cava and cause severe hypotension. To prevent this, the patient will need to be rotated towards the left side at the level of hips or thighs while keeping the head steady. Failure rate following glaucoma filtration surgery is high due to the young age of the patient and physiological changes that occur naturally in pregnancy. Levels of vascular endothelial growth factor (VEGF) and placental growth factor (PGF) are elevated in
pregnancy and aid in cell migration of fibroblasts and inflammatory cells and promote proliferation favoring wound healing. However, the antimetabolites, which are commonly used following filtration surgery, such as Mitomycin C and 5 Fluorouracil are FDA category X teratogens and therefore are absolutely contraindicated in pregnancy. Filtration surgery without the use of antimetabolites, favors fibrosis of the incision site leading to increased chance of failure. An alternative would be MIGS and or aqueous shunt surgery for patients who need surgery in pregnancy. The Tube versus Trabeculectomy study has helped to highlight shunt surgery as an alternative to conventional filtration surgery. Over the last few years, advances in glaucoma surgery have expanded the surgical options available for a pregnant woman with glaucoma, requiring surgery. In MIGS, the ab interno approach prevents damage to the conjunctiva and helps to reduce the number of postoperative medications required. It may also probably be safer compared to traditional filtration procedures. In addition, several microstents are now available which help to increase aqueous outflow with less disturbance to the ocular structures.

Management Plan

Pre-conception counseling: Women in the childbearing age who have a history of glaucoma may already be on anti-glaucoma medications. If the pregnancy is unplanned, it can pose a risk to the fetus since the first trimester is the period of organogenesis and this may be adversely affected by the medication. Hence preconception planning is ideal in women of childbearing age who have glaucoma. Counseling helps the woman understand the potential benefits and risks of various treatment modalities. This will help pave the way for better patient communication and cooperation, including more frequent evaluations of IOP levels, visual field examinations, and optic nerve evaluations, after the baseline evaluations. This, in turn, will help determine the course of management of glaucoma during pregnancy. If the glaucoma is well controlled the woman may be taken off the medication and observed during the course of her pregnancy or the number and frequency of medication may be reduced. In uncontrolled cases, the preconception stage is ideal for any intervention either laser trabeculoplasty or surgical intervention as the risk to the fetus is nil at this stage.

First trimester: By the time the pregnancy is identified, organogenesis would have already started to occur. If pressures can be kept under control without treatment, close monitoring of IOP and visual fields would be the ideal option. Consideration of medications used during first trimester is crucial. Brimonidine, a category B drug, is the safest option and beta-blockers, although a category C drug, can also be used as a first line drug. Surgery may be best avoided in the first trimester.

Second trimester: Beta-blockers and brimonidine can be used with close monitoring of the fetal heart rate and fetal growth during this period. Patient should be educated to watch for symptoms of premature labor if topical prostaglandin analogs are used.

Third trimester: Beta-blockers and CAIs are the ideal medications to be used in this period if IOP lowering is needed. Brimonidine should be stopped late in the third trimester to avoid central nervous system depression in newborn.

Lactation: Both beta-blockers and CAIs can be used during lactation, although beta-blockers are best avoided if the baby has preexisting cardiac problems. Concerning prostaglandins, because of its short half-life, it is unlikely to cause any harm in breastfed infants.
Laser treatment options including trabeculoplasty can be considered if IOP is uncontrolled with medications. Trabeculoplasty: Argon laser, selective laser or micropulse diode laser trabeculoplasty can be performed for better control of IOP. Surgery: Filtration surgery can be performed with caution in second and third trimester if IOP is not controlled by medications and laser trabeculoplasty.

**Conclusion**

Managing glaucoma in pregnancy is a delicate balance between control of IOP to prevent damage to the optic nerve in the mother and avoidance of interventions that are potentially harmful to the fetus. Optimum treatment strategies for glaucoma in pregnancy should begin prior to conception and include careful consideration of risks to both the mother and fetus. Preservation of the optic nerve and vision in the mother are predominate considerations, however, considerations of risk to the unborn child must be carefully considered and discussed with the glaucoma patient. Newer and less invasive surgical interventions such as MIGS may be novel options, however, postoperative medications still need to be considered during the management of glaucoma in pregnancy. An open dialog and close relationship between clinician and females of child-bearing age about the risks and options of pregnancy in glaucoma is vital to producing best possible outcomes for all involved.

**Financial disclosures and Conflict of interest.**

There are no conflicts of interest.

Dr. Alon Harris would like to disclose that he receives remuneration from Shire, CIPLA and AdOM for serving as a consultant. Dr. Harris also holds an ownership interest in AdOM and Oxymap.

All relationships listed above are pursuant to Indiana University’s policy on outside activities.
References


80. Hoy SM. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-

81. Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The 
   Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a 

82. Walter L. The teratogenic activity of pilocarpine, pilocarpidine and their isomers, 
   with special reference to the importance of steric configuration. *J Exp Zool* 1956;

   system. Occurrence, distribution and variation with gestational age of acetylcholine 

84. Samples JR, Meyer BS. Use of ophthalmic medications in pregnant and nursing 


86. Emanuel M E, Gedde S J. Indications for a systemic work-up in glaucoma 
   *Canadian Journal of Ophthalmology* 2014; 49(6): 506-511

87. Geffen N, Assia EI, Melamed S. Laser-Assisted Techniques for Penetrating and 


   

98. Anthony FW, Evans PW, Wheeler T, et al, Variation in detection of VEGF in 
   maternal serum by immunoassay and the possible influence of binding proteins. 
   

   vascular endothelial growth factor receptor-1: novel targets for stimulation of 
   ischemic tissue revascularization and inhibition of angiogenic and inflammatory 

100. Nilforushan N, Yadgari M, Kish SK, et al. Subconjunctival bevacizumab versus 

101. Olali C, Rotchford AP, King AJ. Outcome of repeat trabeculectomies. *Clin 

    Trabeculectomy (TVT) study after five years of follow-up. *Am J Ophthalmol* 2012; 

103. Pillunat LE, Erb C, Jünemann AG, Micro-invasive glaucoma surgery (MIGS): a 
<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class A</td>
<td>Controlled studies show no risk. Adequate well-controlled studies in pregnant women have not shown any risk to the fetus</td>
</tr>
<tr>
<td>Class B</td>
<td>No evidence of risk in humans. Either animal studies have shown risk, but human studies have not or, if no adequate human studies have been done, animal studies are negative.</td>
</tr>
<tr>
<td>Class C</td>
<td>Risk cannot be ruled out. Human studies are lacking, and animal studies are either positive for fetal risk or inadequate as well. However potential benefits may outweigh the potential risk.</td>
</tr>
<tr>
<td>Class D</td>
<td>Definite evidence of risk. Investigational or post-marketing data show some risk to the fetus. But, potential benefits may outweigh the potential risk.</td>
</tr>
<tr>
<td>Class X</td>
<td>Contraindicated in pregnancy. Studies in animals or human or investigational or post-marketing reports have shown fetal risk which clearly outweighs any benefit to the patient.</td>
</tr>
</tbody>
</table>

Table 1: FDA Pregnancy Categories\(^2\)
<table>
<thead>
<tr>
<th>Class</th>
<th>Class</th>
<th>Pregnancy Animal Studies</th>
<th>Humans Theoretical Risk</th>
<th>Documented Cases</th>
<th>Breast-Feeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta Blockers</td>
<td>C</td>
<td>Fetal resorption, delayed fetal ossification</td>
<td>Teratogenicity (in 1st trimester), cardiac rhythm changes, and respiratory changes</td>
<td>Arrhythmia, bradycardia, and impaired respiratory control in newborn</td>
<td>Controversy over drug concentrations in breast milk. Can cause apnea and bradycardia</td>
</tr>
<tr>
<td>Sympathomimetics (i.e. brimonidine)</td>
<td>B</td>
<td>No significant effect</td>
<td>Uterine hypotony / delayed labor</td>
<td>No reported side-effects</td>
<td>CNS depression, hypotension, and apnea</td>
</tr>
<tr>
<td>Carbonic Anhydrase Inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Topical</td>
<td>C</td>
<td>Decreased weight gain and vertebral body malformation</td>
<td>Low birth weight</td>
<td>No reported side-effects</td>
<td>No reported side-effects</td>
</tr>
<tr>
<td>Oral</td>
<td>C</td>
<td>Forelimb anomalies</td>
<td>Limb malformations</td>
<td>One reported case of teratoma</td>
<td>No reported side-effects</td>
</tr>
<tr>
<td>Prostaglandin Analogs</td>
<td>C</td>
<td>High incidence of miscarriage</td>
<td>Uterine contractions</td>
<td>One reported case of miscarriage</td>
<td>No reported side-effects</td>
</tr>
<tr>
<td>Parasympathomimetics</td>
<td>C</td>
<td>Teratogenic</td>
<td>Teratogenicity and dysregulation of placental perfusion</td>
<td>Meningism in the newborn</td>
<td>Seizures, fever, and diaphoresis</td>
</tr>
</tbody>
</table>

Table 2: Adverse Effects of Glaucoma Medications during Pregnancy and Breast-Feeding\(^2\)